Farther Finance Advisors
CHRS icon

Farther Finance Advisors’s Coherus Oncology CHRS Stock Holding History

Farther Finance Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$559 Sell
462
-2,058
-82% -$2.81K ﹤0.01% 5731
2026
Q2 		$3.53K Buy
2,520
+385
+18% +$629 ﹤0.01% 4962
2026
Q1 		$3.71K Buy
2,135
+123
+6% +$218 ﹤0.01% 4637
2025
Q4 		$2.86K Buy
+2,012
New +$2.93K ﹤0.01% 4554
2025
Q2 		– Sell
-47
Closed -$38 – 4530
2025
Q1 		$38 Hold
47
– – ﹤0.01% 4148
2024
Q4 		$65 Buy
+47
New +$53 ﹤0.01% 3845
2024
Q2 		– Sell
-91
Closed -$218 – 3839
2024
Q1 		$218 Buy
91
+88
+2,933% +$217 ﹤0.01% 3251
2023
Q4 		$10 Buy
+3
New +$8 ﹤0.01% 3500

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
RE
Rydar Equities Weatherford, Texas $194M AUM 23.21% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

Farther Finance Advisors's CHRS Position: Q3 2026 in Review

Farther Finance Advisors reduced its Coherus Oncology (CHRS) stake by 82% in Q3 2026, selling an estimated $2.81K and leaving 462 shares worth $559. The position accounts for ﹤0.01% of the portfolio, ranked #5731.

Farther Finance Advisors first reported a position in CHRS in Q4 2023 and has held it in 8 quarters since. The position peaked at $3.71K in Q1 2026. 9 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Farther Finance Advisors held 462 shares of Coherus Oncology worth $559 as of Q3 2026.
  • Farther Finance Advisors sold 2,058 Coherus Oncology shares in Q3 2026, an estimated $2.81K.
  • Coherus Oncology made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5731 holding.
  • Farther Finance Advisors first reported a position in Coherus Oncology in Q4 2023 and has held it in 8 quarters since.
  • Farther Finance Advisors's Coherus Oncology position peaked at $3.71K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.